

LEGISLAÇÃO

[Resolução do Conselho de Ministros n.º 89-A/2020 - Diário da República n.º 208/2020, 1º Suplemento, Série I de 2020-10-26](#)

Presidência do Conselho de Ministros

Determina a limitação de circulação entre diferentes concelhos do território continental no período entre as 00h00 de 30 de outubro e as 06h00 de dia 3 de novembro de 2020

[Declaração de Retificação n.º 40-B/2020 - Diário da República n.º 209/2020, 3º Suplemento, Série I de 2020-10-27](#)

Presidência do Conselho de Ministros - Secretaria-Geral

Retifica a [Resolução do Conselho de Ministros n.º 89-A/2020](#), de 26 de outubro, que determina a limitação de circulação entre diferentes concelhos do território continental no período entre as 00h00 de 30 de outubro e as 06h00 de dia 3 de novembro de 2020

[Lei n.º 62-A/2020 - Diário da República n.º 209/2020, 2º Suplemento, Série I de 2020-10-27](#)

Assembleia da República

Imposição transitória da obrigatoriedade do uso de máscara em espaços públicos

NACIONAL

REGULAÇÃO

[Despacho n.º 10542/2020 - Diário da República n.º 211/2020, Série II de 2020-10-29](#)

Saúde - Gabinete do Secretário de Estado da Saúde

Determina que para efeitos de execução do Plano de Expansão da Capacidade Laboratorial Nacional para diagnóstico de SARS-CoV-2, no ano de 2020, são considerados elegíveis os equipamentos e as infraestruturas, independentemente da modalidade de aquisição, incluindo a aquisição de bens com colocação de equipamento em regime de contra-consumo, das entidades identificadas no anexo do presente despacho, que beneficiam de financiamento no montante de (euro) 8 400 000,00, através do Programa de Financiamento Vertical

[Despacho n.º 10496/2020 - Diário da República n.º 210/2020, Série II de 2020-10-28](#)

Saúde - Gabinete da Ministra

Determina que a título excecional e temporário os profissionais de saúde que se encontrem autorizados a desempenhar funções de triagem no Centro de Contacto do Serviço Nacional de Saúde (SNS24) podem gerar requisições de testes laboratoriais para

MINISTÉRIO DA SAÚDE

SARS-CoV-2, mediante aplicação de algoritmo clínico aprovado pela Direção-Geral da Saúde

[Infarmed participa, pelo 5.º ano consecutivo, na #MedSafetyWeek](#)

[Manhãs Informativas "Regulamento Europeu dos Dispositivos Médicos - Ponto de situação nacional e europeu"](#)

[Indisponibilidade dos sistemas SDIV e FABDM](#)

INFARMED

[Infarmed Newsletter](#)

[Circular informativa n.º 168/CD/2020 de 23/10/2020](#) - SIEXP – Notificação de transações de medicamentos

[Publicação para efeitos do artigo 15º-A do Decreto-Lei n.º 176/2006, de 30 de Agosto](#) - pedidos de autorização de introdução no mercado de medicamentos genéricos.

DGS

[Norma nº 019/2020 de 26/10/2020](#)

COVID-19 : Estratégia Nacional de Testes para SARS-CoV-2

SPMS

[Procedimentos](#)

[2020/ 51](#) - Medicamentos usados nas afeções cutâneas

Medicinal Products for Veterinary Use | Newsletter: [Veterinary Medicines Regulation highlights - Issue 2](#) (new)

Medicinal Products for Human Use | News and press releases: [Extra transparency measures for COVID-19 vaccines and therapeutics](#)

Medicinal Products for Human Use | [Treatments and vaccines for COVID-19](#) (updated)

Medicinal Products for Human Use | [COVID-19: latest updates](#) (updated)

EMA

Medicinal Products for Human Use | [Transparency: exceptional measures for COVID-19 medicines](#) (updated)

Medicinal Products for Human Use | Regulatory and procedural guideline: [Detailed guidance on ICSRs in the context of COVID-19 - Validity and coding of ICSRs](#) (updated)

Medicinal Products for Human Use | News and press releases: [Meeting highlights from the Pharmacovigilance Risk Assessment Committee \(PRAC\) 26-29 October 2020](#)

Medicinal Products for Human Use | [Organisation chart: Human Medicines](#) (updated)

Medicinal Products for Human Use | [Minutes of the CHMP meeting 20-23 July 2020](#) (new)

Medicinal Products for Human and Veterinary Use | News and press releases: [Regulatory update - EMA encourages companies to submit type I variations for 2020 by end of November](#)

[EMA closed 2 November 2020](#)

Medicinal Products for Human Use | [Minutes of the HMPC 6-8 July 2020 meeting](#) (new)

Medicinal Products for Human Use | [Public statement on Vepacel: Withdrawal of the marketing authorisation in the European Union](#) (new)

Medicinal Products for Human Use | [List of medicinal products under additional monitoring](#) (updated)

Medicinal Products for Human Use | [Agenda - EMA 25th anniversary symposium: New approaches in patient-focused cancer drug development](#) (updated)

Medicinal Products for Human Use | [Agenda - PCWP/HCPWP meeting with all eligible organisations: COVID-19 pandemic update](#) (new)

Medicinal Products for Human Use | [PCWP/HCPWP meeting with all eligible organisations: COVID-19 pandemic update](#) , Virtual meeting, from 16/11/2020 to 16/11/2020

Medicinal Products for Human Use | Other: [Lessons learnt from presence of N-nitrosamine impurities in sartan medicines - Implementation plan](#) (new)

Medicinal Products for Human Use | [Nitrosamine impurities](#) (updated)

Medicinal Products for Human Use | [Minutes of the CAT meeting 9-11 September 2020](#) (new)

Agenda: [Agenda and registration form - EMA EudraVigilance information day](#) (updated)

Medicinal Products for Human Use | Agenda: [Agenda - PRAC draft agenda of meeting 26-29 October 2020](#) (new)

Other: [Decision on Amending Budget No 1-2020](#) (new)

Medicinal Products for Human Use | Other: [List of signals discussed at PRAC since September 2012](#) (updated)

Medicinal Products for Human Use | PRAC recommendation on signal: [PRAC recommendations on signals adopted at the 28 September-1 October 2020 PRAC meeting](#) (new)

Medicinal Products for Human Use | PRAC recommendation on signal: [New product information wording: extracts from PRAC recommendations on signals adopted at the 28 September-1 October 2020 PRAC](#) (new)

Medicinal Products for Human Use | Other: [Summary on compassionate use for Sofosbuvir Gilead](#) (updated)

Medicinal Products for Human Use | Other: [Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for Sofosbuvir Gilead available for compassionate use](#) (updated)

Medicinal Products for Human Use | Other: [Summary on compassionate use for Daclatasvir](#) (updated)

Medicinal Products for Human Use | Other: [Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for Daclatasvir available for compassionate use](#) (updated)

Medicinal Products for Human Use | Other: [Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for Ledipasvir/Sofosbuvir available for compassionate use](#) (updated)

Medicinal Products for Human Use | Other: [Summary on compassionate use for Ledipasvir/Sofosbuvir](#) (updated)

Medicinal Products for Human Use | Report: [COMP meeting report on the review of applications for orphan designation: October 2020](#) (new)

Medicinal Products for Human Use | Presentation: [European Network of Paediatric Research at the European Medicines Agency - Introduction](#) (updated)

Medicinal Products for Veterinary Use | [Veterinary pre-submission Q&A: 21-40](#) (updated)

Medicinal Products for Human Use | Agenda: [CHMP ORGAM agenda for the meeting on 5 October 2020](#) (new)

Medicinal Products for Human Use | Report: [CAT monthly report of application procedures, guidelines and related documents on advanced therapies: October 2020](#) (new)

Medicinal Products for Human Use | [COVID-19: latest updates](#) (updated)

CMDh

[Update - Best Practice Guides \(BPGs\) for the Submission and Processing of Variations in the Mutual Recognition Procedure, Chapters 3 and 4](#)

[Update - Examples for acceptable and not acceptable groupings for MRP/DCP products](#)

HMA

[Update - Update Assessment report for Repeat use procedures](#)

[Update - Pharmacovigilance Legislation](#)

[Update - EU ASMF number request form](#)

PSUR Summary of Assessment Reports for [Xonvea](#) and [Cernevit](#)

[Recommendations on submission dates in 2021 for Applicants of the DCP](#)

[Recommendations on submission dates in 2021 for Applications of the MRP](#)

[Coronavirus resurgence: Commission steps up action to reinforce preparedness and response measures across the EU](#)

[President von der Leyen at the World Health Summit](#)

COMISSÃO EUROPEIA

[EU Health Policy Platform webinar - COVID-19 health response package \(29 October 2020, 15.00–16.30 CET\)](#)

[Summary report - Hearing on the organisation of resilient health and social care following the COVID-19 pandemic \(20 October 2020\)](#)
